- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1038/s41418-023-01235-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
- (2023) Hao Zhang et al. Molecular Cancer
- Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants
- (2023) Hyun Ryu et al. ACS Medicinal Chemistry Letters
- The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
- (2022) Alex Cazes et al. Cancers
- Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer
- (2021) Li Liang et al. Cancer Cell International
- Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35
- (2021) Sasha J. Ruiz-Torres et al. ONCOGENE
- Global colorectal cancer burden in 2020 and projections to 2040
- (2021) Yue Xi et al. Translational Oncology
- MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients
- (2020) Brian G. Hunt et al. BREAST CANCER RESEARCH AND TREATMENT
- Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression
- (2020) Camille Sullivan et al. MOLECULAR CANCER RESEARCH
- Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing
- (2020) Cristina Belgiovine et al. Journal of Clinical Medicine
- Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
- (2019) Ramona Graves-Deal et al. Oncotarget
- Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth
- (2018) Huseyin Atakan Ekiz et al. OncoImmunology
- Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis
- (2018) Young-Lan Park et al. TUMORI
- Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
- (2017) Patricia M. LoRusso et al. INVESTIGATIONAL NEW DRUGS
- Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics
- (2016) Jeffery Chakedis et al. Oncotarget
- Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
- (2016) Ben Zhao et al. Oncotarget
- Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
- (2016) Erik S. Linklater et al. Oncotarget
- RON alternative splicing regulation in primary ovarian cancer
- (2015) SEBASTIAN MAYER et al. ONCOLOGY REPORTS
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets
- (2015) Katherine Chang et al. Oncotarget
- A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
- (2014) L. R. Molife et al. CLINICAL CANCER RESEARCH
- Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
- (2014) Chong Sun et al. TRENDS IN BIOCHEMICAL SCIENCES
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer
- (2013) Issa J. Dahabreh et al. ANNALS OF INTERNAL MEDICINE
- Oncogenic Variant RON160 Expression in Breast Cancer and its Potential as a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor
- (2013) Hang-Ping Yao et al. CURRENT CANCER DRUG TARGETS
- The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
- (2011) Hang-Ping Yao et al. Molecular Cancer
- β-Catenin is required for Ron receptor-induced mammary tumorigenesis
- (2011) P K Wagh et al. ONCOGENE
- Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
- (2010) Ming-Hai Wang et al. ACTA PHARMACOLOGICA SINICA
- Identification of a novel series of potent RON receptor tyrosine kinase inhibitors
- (2010) Stéphane Raeppel et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer
- (2008) Chung-Ta Lee et al. DISEASES OF THE COLON & RECTUM
- Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
- (2008) Longbin Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract
- (2008) E. Compérat et al. JOURNAL OF UROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started